Search

Your search keyword '"Giuliana, Mombelli"' showing total 63 results

Search Constraints

Start Over You searched for: Author "Giuliana, Mombelli" Remove constraint Author: "Giuliana, Mombelli"
63 results on '"Giuliana, Mombelli"'

Search Results

1. Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation

2. The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group

3. Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study

4. Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

5. Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients: A randomised controlled trial

6. Influence of body variables in the development of metabolic syndrome-A long term follow-up study.

7. Correction to: Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study

8. The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group

9. Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group

11. A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort

12. Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study)

13. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

14. Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (

15. Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: a randomized, double-blind, placebo controlled study

16. Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)

17. Effects of a nutraceutical combination (bifidobacterium longum BB536, red yeast rice extract) on cholesterol metabolism to oxysterols: a randomized, double-blind, placebo-controlled study in moderate hypercholesterolaemia

18. Left main coronary wall thickness correlates with the carotid intima media thickness and may provide a new marker of cardiovascular risk

19. Systematic Lab Knowledge Integration for Management of Lipid Excess in High-Risk Patients: Rationale and Design of the SKIM LEAN Project

20. Considering gender in prescribing statins: what do physicians need to know?

22. Influence of body variables in the development of metabolic syndrome-A long term follow-up study

23. Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q

24. Correction to: Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study

25. Novel Therapeutic Strategies for the Homozygous Familial Hypercholesterolemia

26. Indicators of cardiovascular risk in metabolic syndrome: long term follow-up in Italian patients

27. Atherosclerosis prevention: the role of biofunctional ingredients of plant foods

28. Clinical response to statins: Mechanism(s) of variable activity and adverse effects

29. Counterpoint: Cholesteryl Ester Transfer Protein Antagonism by Drugs—A Poor Choice

31. Paradoxical Decrease in High-Density Lipoprotein Cholesterol with Fenofibrate: A Quite Rare Phenomenon Indeed

32. Waist-to-Height Ratio Is a Highly Sensitive Index for the Metabolic Syndrome in a Mediterranean Population

33. CETP antagonism versus agonism in cardiovascular prevention and plaque regression

34. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin

35. Familial Hypercholesterolemia and Pregnancy: Risk and Management

36. Development of a model based on body composition to predict drug kinetics II. Application of the model to the use of digoxin in elderlies

37. Efficacy and safety of a nutraceutical with probiotic and red yeast rice extract in patients with moderate hypercholesterolemia: A randomized, double-blind, placebo-controlled study

39. Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention

40. Large waist circumference with normal BMI identifies a significant subset of Italian female patients with the metabolic syndrome—A high risk presentation?

41. Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer

42. Mitochondrial myopathy biomarker Fibroblast growth factor 21 is induced by muscle mtDNA instability and translation defects

43. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus

44. Statin Muscle Toxicity and Genetic Risk Factors

45. Genetic and phenotypic characterization of LDL-receptor in patients with a clinical diagnosis of familial hypercholesterolemia: Two novel mutations

46. Cholesteryl ester transfer protein antagonism by drugs--a poor choice

47. Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed

48. Viability of developing CETP inhibitors

49. Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients

Catalog

Books, media, physical & digital resources